For UK Healthcare Professionals Only
This website contains promotional content and is intended for UK Healthcare Professionals only.
For all other UK residents, please visit www.taihooncology.eu.
Precision targeting in
cholangiocarcinoma1,2
FOENIX-CCA2 was a multinational, open-label, single-arm, phase 2 study that investigated the efficacy and safety of LYTGOBI (futibatinib) in adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic CCA harbouring an FGFR2 fusion or rearrangement (N=103)1
ORR 42%
(n=43/103; 95% CI: 32–52%)1
mDoR 9.7 months
(95% CI: 7.6–17.1)1,3
What is LYTGOBI used for?
LYTGOBI (futibatinib) is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.3
Stay informed
Sign up to our mailing list for regular updates on new content and resources.
Have any questions?
Connect with a Taiho representative for more information.
This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited. The Medicines and Healthcare products Regulatory Agency will review new information on this medicinal product at least every year and the Summary of Product Characteristics will be updated as necessary.3
Please see full Prescribing Information for LYTGOBI (futibatinib) here.
CCA, cholangiocarcinoma; CI, confidence interval; FGFR2, fibroblast growth factor receptor 2; MoA, mechanism of action; mDoR, median duration of response; ORR, objective response rate.
References: 1. Goyal L, et al. N Engl J Med. 2023;388(3):228–239; 2. Sootome H, et al. Cancer Res. 2020;80(22):4986–4997; 3. LYTGOBI Summary of Product Characteristics.